secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001171843-21-007741
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex reports Q3 net loss of $20.5M, cash $423M, CDX-0159 95% complete response.
--------------------------------------------------------------------------------

- Net loss $20.5M ($0.45/share) in Q3 2021; revenue $0.2M, vs net loss $14.2M ($0.36/share) in Q3 2020.
- Cash, cash equivalents & marketable securities $423.1M at Sept 30, 2021, up from $164M at June 30; cash runway through 2025.
- CDX-0159 Phase 1b in inducible urticaria: 95% complete response (18/19) after single dose; median response duration 77+ days (cold urticaria) and 57+ days (symptomatic dermographism).
- Completed $287.5M gross public offering in July 2021; net proceeds $269.9M.
- CDX-1140 combo with pembrolizumab shows confirmed partial response in head and neck cancer; ovarian expansion enrolling for CDX-527.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184321007741/0001171843-21-007741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184321007741/f8k_110921.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-007741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer